Accueil・Liste d'Actions・Denali Therapeutics Inc

Denali Therapeutics Inc

Fermé

SecteurSoins de santé

24.37 -1.58

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

24.3

Max

24.56

Chiffres clés
By Trading Economics
Revenu	894K -128M
Ventes	3.6M 3.6M
BPA	-0.68
Marge bénéficiaire	-3,539.206
Employés	503
EBITDA	1.6M -124M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+47.54% upside

Dividendes
By Acuity
Prochains Résultats	4 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	322M 4B
Ouverture précédente	25.95
Clôture précédente	24.37

Sentiment de l'Actualité

By Acuity

66%

34%

288 / 340 Classement par Healthcare

Denali Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 août 2026, 19:36 UTC

News

Denali Therapeutics reported Q2 revenue of $3.6 million from AVLAYAH, but shares are lower despite expectations for growth in Q3.

12 août 2026, 19:36 UTC

Denali Therapeutics Inc. shares are higher Wednesday, buoyed by positive market sentiment following a modest rise in the core Consumer Price Index.

11 août 2026, 23:21 UTC

Denali Therapeutics Inc shares are higher in after-market trading. No specific company news was identified to explain this movement.

10 août 2026, 19:36 UTC

Correlated Moves

Denali Therapeutics Inc shares declined during Monday's session, tracking broader market trends as the Russell 2000 Index fell. Energy market volatility also influenced the move.

7 août 2026, 19:26 UTC

Social Media

News

Denali Therapeutics shares are lower after a $127.6 million net loss in Q2, missing revenue expectations despite a price target increase from UBS to $34.

6 août 2026, 21:03 UTC

News

Denali Therapeutics shares rise in after-market hours following strong revenue from AVLAYAH and plans to advance Alzheimer's programs despite an EPS miss.

3 août 2026, 19:46 UTC

Correlated Moves

News

Denali Therapeutics received FDA orphan designation for its progranulin therapy for frontotemporal dementia, contributing to a modest rise in shares since Friday's close.

31 juil. 2026, 20:02 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today amid a broader decline in the Biotechnology sub-sector and the Russell 2000 Index.

30 juil. 2026, 19:18 UTC

Correlated Moves

Denali Therapeutics Inc shares are higher, reflecting positive sentiment in the biotech sector amid gains in the broader market and a volatile prior session.

29 juil. 2026, 22:01 UTC

Denali Therapeutics Inc remains unchanged in after-market hours with no specific news. Broader market concerns stem from geopolitical tensions and upcoming Fed decisions.

28 juil. 2026, 18:46 UTC

Denali Therapeutics Inc shares are higher today, though no specific news explains the movement. The stock remains below its 20-day moving average.

27 juil. 2026, 19:56 UTC

Denali Therapeutics Inc is trading higher today, reflecting a notable increase since Friday's close. The stock peaked early before a slight pullback.

24 juil. 2026, 19:26 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower following first-quarter results, continuing a decline amid broader market weakness and a drop in crude oil prices.

22 juil. 2026, 17:46 UTC

Correlated Moves

Denali Therapeutics shares are lower, reflecting broader market trends amid a decline in the Russell 2000 Index. The stock remains below its 20-day moving average.

21 juil. 2026, 17:36 UTC

Correlated Moves

Denali Therapeutics Inc is higher today, recovering from an earlier dip amid positive market sentiment driven by gains in the Russell 2000 and Nasdaq 100 indices.

20 juil. 2026, 23:41 UTC

Correlated Moves

Denali Therapeutics Inc. gained in after-market trading, reflecting a broader trend among correlated assets like Beam Therapeutics Inc. Shares remain below the 20-day moving average.

Comparaison

Variation de prix

Denali Therapeutics Inc prévision

Objectif de Prix

By TipRanks

47.54% hausse

Prévisions sur 12 Mois

Moyen 36 USD 47.54%

Haut 42 USD

Bas 26 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

288 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.